United States · 
What does TCG Crossover invest in?
TCG Crossover invests most often at Series B and Series C (64% of the rounds on record), in sectors such as Well-being, Therapeutics and Drugs.
TCG Crossover highlights
- 01
30 cheques in the last 12 months
- 02
Mostly Series B and Series C: 64% of its rounds
- 03
Led 4 rounds
What they do
TCG Crossover (“TCGX”) is a science-driven investment firm dedicated to advancing disruptive medicinesFrom their own website
- Type
- VC firm
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Well-beingTherapeuticsDrugs
- Based in
- Palo Alto, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first60 appearances
- 2026
25 rounds
- Oct
- Oct
- Oct
- Sept
- Sept
- Aug
- Jul
- Jun
- Jun
- May
- May
- May
- May
- Apr
- Apr
- Apr
- Mar
- Mar
- Feb
- Feb
- Feb
- Jan
- Jan
- Jan
- Jan
- 2025
19 rounds
- Dec
- Dec
- Dec
- Dec
- Nov
- Oct
- Oct
- Oct
- Oct
- Oct
- Sept
- Sept
- Sept
- Aug
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration2 named
CMChen Ming YuManaging Member of the General PartneriFiling they signed
CDCraig David SkalingChief Operating Officer and Chief Compliance OfficeriForm ADV
We also hold 12 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$5.1Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- TCG Crossover Management, LLC
- SEC number
- CRD 311718
Funds on its Form ADV
2 private funds, $2.2B in gross assets · filed Mar 2024
- TCG Crossover Fund I, L.P.Hybrid fund80 investors$1.3B
- TCG Crossover Fund II, L.P.Hybrid fund98 investors$892M
What they claim to have backed
From their own portfolio page (on their website)
13 of 17 we have independently watched raise
AdcendoAktisoncologyArborArtiospharmaCarmotCgoncologyPlexiumRayzebioSynthekineTourmalinebioUpstreambioVersanisbioVicebioAlkeuspharmaKorsanaOllinShoutipharma
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.